ClinicalTrials.Veeva

Menu

Desflurane-induced Myocardial Protection

N

Nobuyuki Katori

Status and phase

Unknown
Phase 4

Conditions

Aortic Valve Stenosis

Treatments

Drug: Desflurane

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT02019797
Desflurane

Details and patient eligibility

About

This study examines pharmacological preconditioning and post conditioning of desflurane by comparing cardiac troponin release in patients receiving either desflurane or propofol for the aortic valve surgery.

Full description

Patients scheduled for aortic valve replacement with use of cardiopulmonary bypass are included in the study. Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a TIVA during the surgery. All patients receive a continuous infusion of remifentanil. Biomarker of myocardial damage troponin I is examined at 4 points; T1: after the induction of anesthesia, T2: arrival at ICU, T3: 12 hours after the ICU arrival, T4: 24 hours after the ICU arrival, T5: third post operative day (3POD).

Enrollment

50 estimated patients

Sex

All

Ages

20 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients scheduled for aortic valve replacement with use of cardiopulmonary bypass.

Exclusion criteria

  • Patients younger than 20 years old.
  • Recent myocardial infarction (within 1 year).
  • Renal dysfunction (GFR less than 50ml/min).
  • Known allergy to study drugs including propofol.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

50 participants in 2 patient groups

Desflurane
Experimental group
Description:
Desflurane inhalation at 1-2 MAC during surgery.
Treatment:
Drug: Desflurane
Propofol
Active Comparator group
Description:
5-8 mg/kg/hr infusion during surgery.
Treatment:
Drug: Desflurane

Trial contacts and locations

1

Loading...

Central trial contact

Nobuyuki Katori, M.D.; Hiroshi Morisaki, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems